254 related articles for article (PubMed ID: 23606201)
21. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
Lee KH; Kim MK; Kim YH; Ryoo BY; Lim HY; Song HS; Kim HK; Lee MA; Im SA; Chang HM; Cho JY; Zang DY; Kim BS; Kim JS
Cancer Chemother Pharmacol; 2009 Jul; 64(2):317-25. PubMed ID: 19034448
[TBL] [Abstract][Full Text] [Related]
22. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
[TBL] [Abstract][Full Text] [Related]
23. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Ch'ang HJ; Huang CL; Wang HP; Shiah HS; Chang MC; Jan CM; Chen JS; Tien YW; Hwang TL; Lin JT; Cheng AL; Whang-Peng J; Chen LT
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1173-9. PubMed ID: 19319535
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
[TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Neri B; Pantaleo P; Giommoni E; Grifoni R; Paoletti C; Rotella V; Pantalone D; Taddei A; Mercatelli A; Tonelli P
Br J Cancer; 2007 Apr; 96(7):1043-6. PubMed ID: 17353926
[TBL] [Abstract][Full Text] [Related]
28. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P; Messinese S; Caraglia M; Marsili S; Piccolomini A; Petrioli R; Ceciarini F; Micheli L; Nencini C; Neri A; Vuolo G; Guarnieri A; Abbruzzese A; Prete SD; Giorgi G; Francini G
Br J Cancer; 2004 May; 90(9):1710-4. PubMed ID: 15150625
[TBL] [Abstract][Full Text] [Related]
29. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Boeck S; Wilkowski R; Bruns CJ; Issels RD; Schulz C; Moosmann N; Laessig D; Haas M; Golf A; Heinemann V
Oncology; 2007; 73(3-4):221-7. PubMed ID: 18424886
[TBL] [Abstract][Full Text] [Related]
30. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Fogelman D; Jafari M; Varadhachary GR; Xiong H; Bullock S; Ozer H; Lin E; Morris J; Cunningham P; Bennett B; Abbruzzese JL; Wolff RA
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1431-8. PubMed ID: 21479635
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
[TBL] [Abstract][Full Text] [Related]
36. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
39. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
